simAbs is a biotech startup specializing in innovative antibody production, offering R&D, manufacturing, and contract development services. The company holds GMP certification, and is expanding its bio manufacturing capabilities.

The company is developing a continuous manufacturing platform to lower costs, improve consistency, and accelerate biologic production, differentiating itself from traditional batch methods.

• Specialises in cutting-edge antibody development, offering comprehensive R&D, manufacturing, and contract services for the biotech sector.
• Committed to quality and safety, holding GMP certification. 
• Driven by innovation, simAbs pioneers continuous manufacturing platforms that reduce costs and setting new standards beyond traditional batch processes.